VIDEO: Better IOL stability observed with fixOflex endocapsular implant
Click Here to Manage Email Alerts
FRANKFURT, Germany — In this Healio Video Perspective from the ESCRS winter meeting, Emmanouil Xylouris, MD, discusses a poster exploring the clinical safety and efficacy of the fixOflex endocapsular implant.
In a study, a group of patients undergoing standard cataract surgery was compared with a group of patients receiving the fixOflex device (Eye PCR). Postoperative outcomes at 6 months were evaluated.
IOP, endothelial cell count and visual outcomes were comparable, “but we also observed better numbers in terms of decentration of the IOL,” Xylouris said. Only 7% of patients in the fixOflex group had decentration of 0.5 mm to 1 mm as compared with almost 20% in the control group with decentration of more than 1 mm.
Implantation time was only 1 minute longer than the standard cataract surgery procedure.
Collapse
Xylouris E, et al. Clinical safety and efficacy of a novel intracapsular reconstructor (fixOflex) in a real-world population: A 6-month follow-up prospective study. Poster presented at: ESCRS winter meeting; Feb. 15-18, 2024; Frankfurt, Germany.
Read more about
Click Here to Manage Email Alerts